Two-Location Independent Retail Pharmacy, Southern California

$10.0M

Revenue

$2.2M

SDE

5.3x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a two-location independent retail pharmacy operating inside medical office buildings in Orange County and San Bernardino County, California. The business posted trailing revenue of $9.95M with $2.17M in adjusted EBITDA, a 21.8% margin that is unusually healthy for retail pharmacy, where independents typically run thin because of PBM reimbursement pressure. The earnings figure was validated by Plante & Moran, a top-15 U.S. CPA firm, through a formal Quality of Earnings review, which is a rare and credibility-boosting detail at this size.

The core strategic asset is location. Both pharmacies sit inside medical office buildings, and 6 of the top 10 prescribers practice in the same building as the pharmacies. This captive prescriber proximity is the moat: patients fill where their doctor is, and script flow follows the physicians. The operation runs a modern tech stack (PioneerRx, Parata robotic dispensing and verification, AlignRx PSAO, 2D barcode scanning) plus an AI bot processing prescriptions 24/7, which lowers labor intensity and supports the margin story.

The owner is not active in day-to-day operations, and both Pharmacists-in-Charge are long-tenured and expected to stay. Growth is in flight: a drive-through under construction, 470+ assisted-living-facility beds in long-term-care pipeline discussions, and active Medicare Part B DMEPOS billing and mass immunizer infrastructure. The seller frames all of this as uncredited upside, which is the kind of claim a buyer should verify rather than pay for.

Why we like it

Earnings quality is unusually well-documented for a sub-$12M deal. A $2.17M EBITDA number that survived a formal Plante & Moran Quality of Earnings review carries far more weight than seller-prepared statements, and the 21.8% margin is strong for retail pharmacy where 3-5% net is common. The +37% YoY EBITDA growth, if durable and not a reimbursement anomaly, changes the effective multiple materially.
The moat is physical and hard to replicate. With 6 of the top 10 prescribers in the same building and a regional hospital steps away with shared parking, script capture is structural rather than promotional. A competitor cannot easily lease their way into the same prescriber adjacency, and that proximity is the single biggest reason these two units outperform typical independents.
Prescriptions are recurring by nature. Maintenance medications refill month after month for chronic conditions, and pharmacy demand does not soften in a recession because people do not stop taking their heart, diabetes, or blood pressure drugs. That combination of recurring refill revenue and non-discretionary demand is exactly the durable cash flow profile worth paying for.
The business is already manager-run. The owner is not in daily operations and both Pharmacists-in-Charge are long-tenured and likely to remain, which means a buyer inherits a functioning team rather than a job. That absentee structure plus a modern automation stack (robotic dispensing, AI prescription processing) makes this ownable by a financial buyer or a multi-unit operator.

How to improve it

Convert the LTC pipeline into signed contracts fast. The 470+ ALF beds in advanced discussions are the highest-margin, stickiest revenue in pharmacy, and long-term-care facility contracts lock in predictable monthly script volume. Prioritize closing these agreements in the first 90 days because they compound and are defensible against retail chain competition.
Fully monetize the Medicare Part B DMEPOS and immunizer infrastructure. The billing rails are described as active but not yet reflected in earnings, so build out durable medical equipment fulfillment and a structured immunization program (flu, shingles, COVID, travel). These are higher-margin adjacencies that leverage the existing prescriber relationships already in the building.
Complete and merchandise the drive-through immediately. Permits are pulled and ground is broken, so finish the buildout and use it to capture refill convenience volume and reduce in-store labor. Drive-through also improves capture of the hospital-discharge and time-pressed patient segments near the shared-parking location.
Deepen front-end and clinical service revenue. Independent pharmacies with captive prescriber traffic can layer in medication therapy management, adherence packaging, and specialty compounding, all of which carry better margins than commodity dispensing. This diversifies away from PBM reimbursement risk that pressures the core fill business.
Optimize the PSAO and reimbursement contracts. Run a full analysis of AlignRx PSAO terms, DIR fees, and payer mix to identify underwater scripts and negotiate or re-route where possible. Small improvements in gross-margin-per-script across 100k+ fills compound directly to EBITDA in a business this reimbursement-sensitive.
Scale the AI and automation stack across both units and beyond. The AI bot and Parata robotics already lower labor cost, so document the workflow and standardize it as a template for acquiring or opening additional med-office-building locations. The playbook here is a repeatable roll-up model anchored on prescriber proximity.

Diligence notes

Interrogate the +37% EBITDA growth and reimbursement dynamics. Pharmacy earnings can spike from one-off script categories, favorable DIR fee timing, or a single high-value drug, so break down revenue by drug class and payer to confirm the growth is structural. Understand DIR clawback exposure and how future PBM reimbursement changes could compress the 21.8% margin.
Verify prescriber concentration risk. The moat depends on 6 of the top 10 prescribers in the same building, but that also means script flow is dangerously tied to a handful of physicians. Model what happens if two or three of those prescribers retire, relocate, or shift referral patterns, because that is the primary downside case.
Confirm lease assumability and remaining term at both med-office locations. Since the entire value thesis rests on being inside those specific buildings, the leases are the real crown jewels, not the equipment. Nail down remaining term, renewal options, rent escalators, and whether the landlord can lease adjacent space to a competing pharmacy.
Validate PIC retention and licensing continuity. A stock sale with absentee ownership only works if the Pharmacists-in-Charge stay, so secure employment agreements and non-competes before close. Confirm both PICs hold clean licenses and that DEA registrations, state board standing, and controlled-substance compliance transfer cleanly in a stock deal.
Pressure-test the uncredited upside claims. The seller says the LTC beds, DMEPOS billing, and drive-through add value not reflected in price, which is convenient framing that a buyer should not pay for until proven. Get the actual status of the 470+ ALF discussions, DMEPOS billing volume to date, and drive-through construction timeline and cost to complete.
Review the full Plante & Moran QoE workbook and working capital needs. Get the complete workbook post-IOI and reconcile adjustments, add-backs, and normalized inventory. Pharmacy carries significant drug inventory and receivables from payers, so quantify the working capital peg required at close so it is not a hidden add to the effective purchase price.

Source

Originally listed on BizBen. View original listing →